Computer-assisted molecular modeling: indispensable tools for molecular pharmacology.

Abstract:

:Ball-and-stick mechanical models, typically associated with chemists, have been helpful in understanding structural problems and the relationship between structure and biologic activity. With progress in computer speed, graphics performance, and software innovation, molecules of biological interest can be subjected to rigorous calculations. Computational chemistry and biology are rooted in the belief that theoretical physics can be used to calculate accurate molecular structures. Although in its infancy, computer-assisted molecular modeling is gaining attention and acceptability as an increasing number of researchers turn their attention toward rational molecular design. The trend to use theoretical methods can be traced to the greater availability of computer graphics work-stations, decreasing computer costs, faster central processing units, more robust algorithms, and "user-friendly" software codes. Every major pharmaceutical company has invested in these resources to reduce the time it takes to design and develop pharmaceutical agents. Because of the vast financial and manpower investments needed to introduce a single drug, medicinal chemists and pharmacologists are interested in understanding and predicting drug action at the molecular level. Although drug action is still poorly understood, molecular modeling should reduce some of the labor in the development of pharmaceutical agents.

journal_name

J Clin Pharmacol

authors

Bowen JP,Charifson PS,Fox PC,Kontoyianni M,Miller AB,Schnur D,Stewart EL,Van Dyke C

doi

10.1002/j.1552-4604.1993.tb03915.x

subject

Has Abstract

pub_date

1993-12-01 00:00:00

pages

1149-64

issue

12

eissn

0091-2700

issn

1552-4604

journal_volume

33

pub_type

杂志文章,评审
  • Evaluation of Evolocumab (AMG 145), a Fully Human Anti-PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment.

    abstract::Evolocumab binds PCSK9, increasing low-density lipoprotein cholesterol (LDL-C) receptors and lowering LDL-C. Target-mediated evolocumab elimination is attributable to PCSK9 binding. As circulating PCSK9 and LDL-C levels are primarily regulated by the liver, we compared evolocumab pharmacokinetics, pharmacodynamics, an...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/jcph.832

    authors: Gibbs JP,Slatter JG,Egbuna O,Geller M,Hamilton L,Dias CS,Xu RY,Johnson J,Wasserman SM,Emery MG

    更新日期:2017-04-01 00:00:00

  • Clinical pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-Genistein in patients with B-lineage lymphoid malignancies.

    abstract::The authors examined the pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-Genistein in 17 patients (4 children, 13 adults) with B-lineage lymphoid malignancies, including 12 patients with acute lymphoblastic leukemia (ALL) and 5 patients with non-Hodgkin's lymphoma (NHL). The immunoconjugat...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1177/00912709922012051

    authors: Chen CL,Levine A,Rao A,O'Neill K,Messinger Y,Myers DE,Goldman F,Hurvitz C,Casper JT,Uckun FM

    更新日期:1999-12-01 00:00:00

  • Interaction trial between artemether-lumefantrine (Riamet) and quinine in healthy subjects.

    abstract::Forty-two healthy Caucasian subjects were randomized in a double-blind, parallel three-group study (14 subjects per group) to investigate potential electrocardiographic and pharmacokinetic interactions between the antimalarials artemether-lumefantrine (six-dose regimen of Riamet over 3 days) and quinine (2-h intraveno...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1177/009127002401382632

    authors: Lefèvre G,Carpenter P,Souppart C,Schmidli H,Martin JM,Lane A,Ward C,Amakye D

    更新日期:2002-10-01 00:00:00

  • Aminoglutethimide in the treatment of Cushing's syndrome.

    abstract::The efficacy and tolerability of aminoglutethimide for the treatment of Cushing's syndrome was assessed in 66 cases three of which are described in the present paper. Aminoglutethimide provided palliation from the signs and symptoms of hypercorticism in 13 of 21 patients with metastatic adrenocortical carcinoma and fo...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1976.tb01504.x

    authors: Misbin RI,Canary J,Willard D

    更新日期:1976-11-01 00:00:00

  • Fluoxetine bioequivalence study: quantification of fluoxetine and norfluoxetine by liquid chromatography coupled to mass spectrometry.

    abstract::In this study, the authors assessed the bioequivalence of two fluoxetine tablet formulations in 24 healthy volunteers of both sexes who received a single 20 mg dose of each fluoxetine formulation, and a new sensitive method for the quantification of fluoxetine and norfluoxetine in human plasma was developed. The study...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1177/00912709922011827

    authors: Moraes MO,Lerner FE,Corso G,Bezerra FA,Moraes ME,De Nucci G

    更新日期:1999-10-01 00:00:00

  • The effect of lovastatin on early restenosis.

    abstract::The effect of lovastatin given before percutaneous coronary angioplasty (PTCA) on early restenosis was investigated in men with mild to moderate hypercholesterolemia. Thirty-four hypercholesterolemic patients (serum LDL cholesterol 130-200 mg/dL) undergoing their first PTCA completed a 6-month prospective, double-blin...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1002/j.1552-4604.1995.tb05017.x

    authors: Beigel Y,Zafrir N,Teplitzky Y,Neuman Y,Gavish D,Wurzel M,Fainaru M

    更新日期:1995-06-01 00:00:00

  • Influence of severe renal impairment on the pharmacokinetics of clazosentan.

    abstract::The purpose of this open-label, parallel-group study was to investigate the effect of severe renal impairment on the pharmacokinetics (PK), tolerability, and safety of clazosentan, an intravenous endothelin receptor antagonist. Clazosentan was administered as a continuous intravenous infusion of 1 mg/h for a period of...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1177/0091270010368975

    authors: Bruderer S,Sasu B,Tsvitbaum N,Dingemanse J

    更新日期:2011-03-01 00:00:00

  • The metabolism of floctafenin in man and rodents.

    abstract::Floctafenin (FFn), 2,3-dihydroxypropyl--N--(8--trifluoromethyl--4--quinolyl) anthranilate, a new nonnarcotic analgesic drug, was studied in man, mice, and the isolated perfused rat liver. In all species the drug is rapidly hydrolyzed to floctafenic acid (FFa). In seven volunteer subjects who each received a single ora...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1979.tb01613.x

    authors: Lynn RK,Holm R,Swanson BN,Smith R,Gerber N

    更新日期:1979-01-01 00:00:00

  • Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropositive for the human immunodeficiency virus.

    abstract::The steady-state pharmacokinetics of didanosine (DDI) and ketoconazole (KET) were evaluated when the agents were administered alone or concurrently to patients seropositive for the human immunodeficiency virus. Using a randomized, three-way crossover design, multiple oral doses of DDI (375 mg twice daily for 4 days), ...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1002/j.1552-4604.1993.tb01921.x

    authors: Knupp CA,Brater DC,Relue J,Barbhaiya RH

    更新日期:1993-10-01 00:00:00

  • Long-term efficacy and toxicity of high- and low-dose amiodarone regimens.

    abstract::Amiodarone is an effective antiarrhythmic drug for the control of potentially lethal and lethal ventricular arrhythmias (VA). In the United States, a high-dose regimen has been used at the expense of a high toxicity profile for the control of lethal VAs. Significant antiarrhythmic efficacy has also been established wi...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1002/j.1552-4604.1989.tb03354.x

    authors: Kerin NZ,Aragon E,Faitel K,Frumin H,Rubenfire M

    更新日期:1989-05-01 00:00:00

  • Epoprostenol (PGI2, prostacyclin) during high-risk hemodialysis: preventing further bleeding complications.

    abstract::The frequency of hemodialysis-associated hemorrhage was studied prospectively in two successive, parallel, heparin-controlled studies using epoprostenol (PGI2; average dose, 4.1 ng/kg.min) as the sole antithrombotic agent. Sixty-three patients with active or recently active bleeding underwent 163 hemodialysis treatmen...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1988.tb03222.x

    authors: Swartz RD,Flamenbaum W,Dubrow A,Hall JC,Crow JW,Cato A

    更新日期:1988-09-01 00:00:00

  • Midazolam disposition in patients undergoing continuous venovenous hemodialysis.

    abstract::The aim of the study was to investigate the pharmacokinetics and removal of midazolam and unconjugated and glucuronidated 1-hydroxy-midazolam in 4 intensive care patients on continuous venovenous hemodialysis. Plasma midazolam and its metabolites were assessed by HPLC from blood samples collected during continuous inf...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1177/00912700122010933

    authors: Bolon M,Bastien O,Flamens C,Paulus S,Boulieu R

    更新日期:2001-09-01 00:00:00

  • Estimation of the elimination half-life of a drug at any serum concentration when the Km and Vmax of the drug are known: calculations and validation with phenytoin.

    abstract::A method of estimating the elimination half-life of a drug at any selected serum concentration when the Km and Vmax of that drug are known is described. The method was validated in six patients by determining their Km and Vmax values for phenytoin, using data obtained at two serum concentrations and then using the Km ...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1987.tb03022.x

    authors: Browne TR,Greenblatt DJ,Evans JE,Szabo GK,Evans BA,Schumacher GE

    更新日期:1987-04-01 00:00:00

  • Pharmacology and pharmacokinetics of amiodarone.

    abstract::Amiodarone is a unique antiarrhythmic agent originally developed as a vasodilator. Classified electrophysiologically as a Type III antiarrhythmic, it also has both nonspecific antisympathetic and direct, fast channel-membrane effects. Hemodynamic effects of orally administered amiodarone (a negative inotropic agent) a...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1002/j.1552-4604.1991.tb03673.x

    authors: Freedman MD,Somberg JC

    更新日期:1991-11-01 00:00:00

  • Comparisons of the analgesic effects of oral and intramuscular oxymorphone and of intramuscular oxymorphone and morphine in patients with cancer.

    abstract::The relative analgesic potency of oral and intramuscular oxymorphone was evaluated in a double-blind crossover comparison of graded single doses in patients with chronic pain due to cancer. When both duration and intensity of analgesia are considered (total effect), oral oxymorphone was 1/6 as potent as the intramuscu...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1177/009127007701700402

    authors: Beaver WT,Wallenstein SL,Houde RW,Rogers A

    更新日期:1977-04-01 00:00:00

  • Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrations.

    abstract::Anemia is a well-known RBV-related event in HCV therapy which is exacerbated by the addition of telaprevir and boceprevir. This retrospective study evaluated and compared ribavirin exposure and parameters able to influence hemoglobin decrease in a large population of patients treated with dual or triple therapy. Patie...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/jcph.454

    authors: Bodeau S,Nguyen-Khac E,Solas C,Bennis Y,Capron D,Duverlie G,Brochot E

    更新日期:2015-05-01 00:00:00

  • Electrophysiologic properties of the cannabinoids.

    abstract::The effects of the psychoactive cannabinoid delta 9-tetrahydrocannabinol (THC) and the nonpsychoactive cannabinoid cannabidiol (CBD) were investigated comparatively on electrically caused transcallosal cortical evoked responses, electrically induced limbic after discharges, photically evoked cortical afterdischarges, ...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1981.tb02625.x

    authors: Turkanis SA,Karler R

    更新日期:1981-08-01 00:00:00

  • Trial treatment length optimization with an emphasis on disease progression studies.

    abstract::Optimal design has been used in the past mainly to optimize sampling schedules for clinical trials. Optimization on design variables other than sampling times has been published in the literature only once before. This study shows, as an example, optimization on the length of treatment periods to obtain reliable estim...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1177/0091270008329560

    authors: Hennig S,Nyberg J,Hooker AC,Karlsson MO

    更新日期:2009-03-01 00:00:00

  • Population Pharmacokinetics and Exposure-Response Analyses for CPX-351 in Patients With Hematologic Malignancies.

    abstract::CPX-351, a dual-drug liposomal encapsulation of cytarabine and daunorubicin at a synergistic ratio, is approved in the United States for adults with newly diagnosed therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes. Population pharmacokinetics analyses were performed ...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/jcph.1366

    authors: Wang Q,Banerjee K,Vasilinin G,Marier JF,Gibbons JA

    更新日期:2019-05-01 00:00:00

  • Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study.

    abstract::This multicenter, randomized, open-label, parallel-group, phase-1 study assessed the pharmacokinetics (PK), safety, and tolerability of the investigational intramuscular paliperidone palmitate 3-month (PP3M) formulation in patients with schizophrenia or schizoaffective disorder. A total of 328 patients (men or women, ...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1002/jcph.597

    authors: Ravenstijn P,Remmerie B,Savitz A,Samtani MN,Nuamah I,Chang CT,De Meulder M,Hough D,Gopal S

    更新日期:2016-03-01 00:00:00

  • Probiotics in Disease Prevention and Treatment.

    abstract::Few treatments for human diseases have received as much investigation in the past 20 years as probiotics. In 2017, English-language meta-analyses totaling 52 studies determined the effect of probiotics on conditions ranging from necrotizing enterocolitis and colic in infants to constipation, irritable bowel syndrome, ...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/jcph.1121

    authors: Liu Y,Tran DQ,Rhoads JM

    更新日期:2018-10-01 00:00:00

  • Factors influencing procainamide total body clearance in the immediate postmyocardial infarction period.

    abstract::Fifteen acute myocardial infarction patients (only one of whom had evidence of significant renal dysfunction) received a constant-rate intravenous infusion of procainamide at one rate for a least 24 hours. Steady-state plasma levels achieved during these infusions were used to calculate total body clearance (C/B). Lin...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1981.tb01727.x

    authors: Wyman MG,Goldreyer BN,Cannon DS,Ludden TM,Lalka D

    更新日期:1981-01-01 00:00:00

  • Efficacy of acebutolol in chronic stable angina using single-blind and randomized double-blind protocol.

    abstract::The clinical effects of a cardioselective beta-adrenergic blocking drug, acebutolol, were studied in 25 patients with chronic stable angina, using a seven-week single-blind placebo leads to acebutolol (mean dose 913 mg/day) phase followed by 12-week randomized double-blind placebo leads to acebutolol (mean dose 968 mg...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1002/j.1552-4604.1982.tb02688.x

    authors: Lee G,DeMaria AN,Favrot L,Hermanovich J,Kozina J,Krieg P,Kimchi A,Laddu A,Mason DT

    更新日期:1982-08-01 00:00:00

  • Efficacy of cardioselective beta-adrenergic blockade with intravenously administered metoprolol in the treatment of supraventricular tachyarrhythmias.

    abstract::The efficacy of intravenously administered metoprolol, a cardioselective beta-adrenergic blocking agent, was evaluated in the treatment of supraventricular tachyarrhythmias in 16 patients. The arrhythmias that were treated were atrial fibrillation (11 patients), atrial flutter (2 patients), supraventricular tachycardi...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1002/j.1552-4604.1991.tb03765.x

    authors: Amsterdam EA,Kulcyski J,Ridgeway MG

    更新日期:1991-08-01 00:00:00

  • Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects.

    abstract::Suvorexant is an orexin receptor antagonist for treating insomnia. The maximum approved dose in the United States and Japan is 20 mg. We evaluated suvorexant effects on respiration during sleep in a randomized, double-blind, 3-period crossover study of healthy adult men (n = 8) and women (n = 4) ≤ 50 years old who rec...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/jcph.523

    authors: Uemura N,McCrea J,Sun H,Donikyan M,Zammit G,Liu R,Louridas B,Marsilio S,Lines C,Troyer MD,Wagner J

    更新日期:2015-10-01 00:00:00

  • Enalapril in the management of hypertension associated with renal artery stenosis.

    abstract::Enalapril maleate (MK-421) is a new non-sulfhydryl-containing converting-enzyme inhibitor that has been shown to be effective and well tolerated in patients with essential hypertension. Data on its effectiveness and safety in patients with renovascular hypertension are limited and have involved predominantly short-ter...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1177/009127008702700105

    authors: Canzanello VJ,Madaio MP,Madias NE

    更新日期:1987-01-01 00:00:00

  • Population pharmacokinetic analysis of Ibuprofen enantiomers in preterm newborn infants.

    abstract::The aim of this pharmacokinetic analysis was to develop and validate a population pharmacokinetic model for R- and S-ibuprofen from samples obtained after 3 successive administrations of ibuprofen (10-5-5 mg/kg) at 24-hour intervals to preterm newborn infants aged from <6 hours to 8 days of life. A model including uni...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1177/0091270008323752

    authors: Gregoire N,Desfrere L,Roze JC,Kibleur Y,Koehne P

    更新日期:2008-12-01 00:00:00

  • Use of reflectance spectrophotometry in the human corticosteroid skin blanching assay.

    abstract::A reflectance spectrophotometric method for evaluation of the skin blanching response to topical corticosteroids was evaluated. This blanching response is used, for drug development and regulatory purposes, to assess potency and bioequivalence of topical corticosteroid products. The common method involves the use of a...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1993.tb05611.x

    authors: Conner DP,Zamani K,Almirez RG,Millora E,Nix D,Shah VP

    更新日期:1993-08-01 00:00:00

  • Systemic availability and pharmacokinetics of thymol in humans.

    abstract::Essential oil compounds such as found in thyme extract are established for the therapy of chronic and acute bronchitis. Various pharmacodynamic activities for thyme extract and the essential thyme oil, respectively, have been demonstrated in vitro, but availability of these compounds in the respective target organs ha...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1177/009127002401102678

    authors: Kohlert C,Schindler G,März RW,Abel G,Brinkhaus B,Derendorf H,Gräfe EU,Veit M

    更新日期:2002-07-01 00:00:00

  • Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole.

    abstract::It is well known that the CYP2C19 genetic polymorphism influences the pharmacokinetics and pharmacodynamics of proton pump inhibitors (PPIs), but no report has addressed the effects on ilaprazole, a newly developed PPI. To investigate the effects of the CYP2C19 genetic polymorphism on the disposition and pharmacodynam...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1177/0091270011408611

    authors: Cho H,Choi MK,Cho DY,Yeo CW,Jeong HE,Shon JH,Lee JY,Shin JS,Cho M,Kim DY,Shin JG

    更新日期:2012-07-01 00:00:00